Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Share-based Compensation: 2019-2024

Historic Share-based Compensation for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to $9.1 million.

  • GeneDx Holdings' Share-based Compensation rose 191.14% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.2 million, marking a year-over-year increase of 368.82%. This contributed to the annual value of $9.1 million for FY2024, which is 2903.07% up from last year.
  • As of FY2024, GeneDx Holdings' Share-based Compensation stood at $9.1 million, which was up 2,903.07% from -$326,000 recorded in FY2023.
  • In the past 5 years, GeneDx Holdings' Share-based Compensation ranged from a high of $219.4 million in FY2021 and a low of -$326,000 during FY2023.
  • For the 3-year period, GeneDx Holdings' Share-based Compensation averaged around $16.9 million, with its median value being $9.1 million (2024).
  • In the last 5 years, GeneDx Holdings' Share-based Compensation crashed by 100.78% in 2023 and then surged by 2,903.07% in 2024.
  • GeneDx Holdings' Share-based Compensation (Yearly) stood at $120.2 million in 2020, then skyrocketed by 82.50% to $219.4 million in 2021, then plummeted by 80.87% to $42.0 million in 2022, then crashed by 100.78% to -$326,000 in 2023, then soared by 2,903.07% to $9.1 million in 2024.